Clinical Trials · NCT02974244
Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 7,000
- Start date
- Oct 2014
- Locations
- 1 site, United States
- Primary endpoint
- Changes from baseline in HbA1c (%)